Drug General Information
Drug ID
Former ID
Drug Name
Indication Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] Phase 1/2 [1]
Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 [2]
Taiho oncology
Target and Pathway
Target(s) Fibroblast growth factor (FGF) Target Info Inhibitor [2]
Fibroblast growth factor receptor (FGFR) Target Info Antagonist [3]
REF 1 ClinicalTrials.gov (NCT02052778) A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities. U.S. National Institutes of Health.
REF 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 3 TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.